stockrow
Friday 6 November 2026
Export OPTH’s income statement to Excel — free account
Optimi Health Corp.
OPTH Healthcare Drug Manufacturers Specialty & Generic
Optimi Health Corp.’s revenue for fiscal 2025 (year ended September 2025) was $304,800.00, up 6.39% from fiscal 2024.
2.29
0.08
+3.62%
Follow OPTH
Alert me
| Mar '26 | Dec '25 | Jun '25 | Sep '24 | |
|---|---|---|---|---|
P/S ratio |
0.00 | — | 0.00 | — |
P/FCF ratio |
0.00 | — | 0.00 | — |
P/Operating CF |
(80.63) | — | (359.30) | — |
P/B ratio |
7.83 | — | 57.93 | — |
Price to Tangible BV |
7.83 | — | 57.93 | — |
EV/Sales |
0.00 | — | 0.00 | — |
EV/EBITDA |
0.00 | — | 0.00 | — |
EV/Operating CF |
(4.78) | — | 0.00 | — |
EV/FCF |
(4.65) | — | 0.00 | — |
Quick Ratio |
0.02 | 0.07 | 0.09 | 0.07 |
Current Ratio |
0.06 | 0.12 | 0.29 | 0.38 |
Net Debt/EBITDA |
(3.10) | (3.06) | 0.14 | 0.00 |
Debt/Assets |
26.60% | 25.29% | 0.00% | 0.00% |
Debt/Equity |
1.02 | 0.72 | 0.00 | 0.00 |
Operating CF/Net income |
0.22 | 0.41 | 1.38 | 0.00 |
Capex/Depreciation |
(0.05) | (0.01) | (0.02) | (0.18) |
Interest Coverage |
(5.73) | (4.59) | (5.71) | — |
Research and Development Expense of Revenue |
39.03% | 0.00% | 0.77% | — |
Selling, General and Administrative Expense of Revenue |
389.38% | 0.00% | 123.59% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
113.93% | 0.00% | 23.38% | — |
Graham Net Nets |
(0.34) | — | (0.01) | — |
Graham Number |
0.00 | — | 0.00 | — |
Free Cash Flow Yield |
(24.23%) | — | 0.00% | — |
Revenue per Share |
0.02 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.08) | (0.14) | (0.01) | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.08) | (0.14) | (0.01) | 0.00 |
Cash per Share |
0.02 | 0.11 | 0.00 | 0.00 |
Shareholders Equity per Share |
0.80 | 1.12 | 0.06 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.80 | 1.12 | 0.06 | 0.00 |
Free Cash Flow |
(0.26) | (0.46) | (0.91) | (3.26) |
Working Capital |
(6.76) | (5.71) | (1.86) | (1.46) |
Capital Expenditures |
(0.01) | 0.00 | (0.01) | (0.11) |
Net Current Asset Value |
(6.86) | (5.82) | (3.85) | (2.75) |
EV/EBIT |
0.00 | — | 0.00 | — |
Capex to Sales |
0.11 | 0.00 | 0.08 | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026